roche__tree

EU approval for Roche’s Polivy combo in relapsed/refractory B-cell lymphoma

pharmafile | January 21, 2020 | News story | Manufacturing and Production, Sales and Marketing Cancer, Polivy, Roche, lymphoma, pharma 

The European Commission has awarded conditional marketing approval to Roche’s Polivy (polatuzumab vedotin), it has been revealed. The therapy is authorised for the treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), when combined with bendamustine plus MabThera (rituximab), for patients who are not candidates for a haematopoietic stem cell transplant.

Roche announced that the Phase 1b/2 results submitted in support of the application were the first and only to show superiority of a drug versus the commonly used regimen of bendamustine plus MabThera alone. Specifically, the Polivy regimen generated complete response rates of 40% compared to just 17.5 with bendamustine plus MabThera alone, while overall survival was more than doubled to a median of 12.4 months compared to 4.7 months.

Additionally, median duration of response was recorded as 10.3 months with the Polivy regimen compared to 4.1 months.

“With this approval, people in the EU with relapsed or refractory diffuse large B-cell lymphoma will have the opportunity to benefit from this new Polivy combination,” remarked Levi Garraway, Roche’s Chief Medical Officer and Head of Global Product Development. “For patients battling this aggressive disease, the prognosis is poor and few treatments are available. We are proud to bring this first-in-class treatment option to those who need it most.”

Matt Fellows

Related Content

Roche’s Alecensa approved by FDA as lung cancer treatment

Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …

Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment

Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has …

Geneos Therapeutics shares data from phase 1/2 trial for cancer vaccine

Geneos Therapeutics has announced that it has published positive safety, immunogenicity and efficacy data from …

Latest content